Dashboard/ARWR/plozasiran/event

ReadoutTopline Readout

Plozasiran PALISADE Phase 3 FCS Topline

ARWR·plozasiran·Familial Chylomicronemia·

Phase 3

·NCT06028386

current best date

'27

QTR8 months

Takeaway

Phase 3 efficacy readout for Arrowhead’s wholly-owned plozasiran (APOC3 siRNA) in familial chylomicronemia syndrome (FCS). Same indication: Ionis’s olezarsen (PDUFA 2026-12-19). Watch: triglyceride reduction at month 12, acute pancreatitis events.

What’s at stake

market · comparables · base rate · prior moves

Market opportunity

—

company filings

Peer comparables

1 readout

ClinicalTrials.gov

Stage base rate

~58%

BIO Industry Analysis 2023 (2011–2020)

Avg prior-readout move

—

historical price reactions

MoAAPOC3-targeting RNAi

Plozasiran is a quarterly subcutaneous RNAi therapy developed by Arrowhead Pharmaceuticals that silences the APOC3 gene in liver cells to dramatically reduce apolipoprotein C-III (ApoC-III) — a protein that inhibits the triglyceride-clearing enzyme lipoprotein lipase. In familial chylomicronemia syndrome (FCS), biallelic LPL mutations make patients genetically unable to clear dietary fat, producing triglyceride levels that can exceed 1,000 mg/dL and recurrent life-threatening pancreatitis attacks; ApoC-III suppression restores the patient's residual triglyceride clearance capacity. Plozasiran is in a Phase 3 pivotal trial (PALISADE) for FCS, competing directly with Ionis's olezarsen in the same indication.

Indication

Cardio-Renal

Familial Chylomicronemia

MeSH · D006949

No primer in glossary yet.

Trial

recruiting

NCT06028386 ↗

PALISADE Phase 3 Plozasiran in FCS

Glossary · what this readout is measuring

2 terms detected in the takeaway

siRNAmodality
Small interfering RNA
RNA-based drug that silences a target gene by triggering mRNA degradation. Hepatic gene silencing is the dominant use case.
PDUFAregulatory
Prescription Drug User Fee Act
The FDA's self-imposed review deadline for an NDA/BLA. Standard reviews are ~10 months from filing; priority reviews are ~6 months.

Sector base rates · reference data

historical record · not prediction

of 2 historical Phase 3 readouts in Cardio-Renal: 1 positive, 1 mixed, 0 negative.

Positive

1/ 2

50%

Mixed

1/ 2

50%

Negative

0/ 2

positive rate 50% · primary endpoint hit rate 100%

Reference data · comparable readouts

How Ph3 readouts in Cardio-Renal have landed.

Reference, not prediction. We surface the historical record so you can read it yourself. We never extrapolate to the upcoming event.

Positive

1/2

50% in record

Primary endpoint hit

100%

across 2 readouts

Drug · sponsorPhase · yearOutcomeKey metricSource

omecamtiv mecarbil

CYTK · HF

Ph3 · Oct 2022mixednarrow CV-death/HF benefit; FDA declinedFDA

finerenone (FIDELIO-DKD)

BAYRY · CKD

Ph3 · Jul 2020positive18% reduction in primary compositePR

sorted by phase match, then recency · sources span PR wires, CT.gov, FDA notices, and conference presentations · we never editorialize the outcome label

Competitive landscape

4 peers in Cardio-Renal · ranked by indication + modality match

Drug	Company	Modality	Mechanism	Next catalyst
olezarsen	IONS	oligonucleotide	ApoCIII antisense oligonucleotide	PDUFA · Dec 26
AMVUTTRAvutrisiran	ALNY	siRNA	TTR-targeting RNAi	PDUFA · Dec 26
VERVE-102	VERV	gene therapy	LNP-delivered base editor targeting PCSK9	INTERIM · Nov 26
XPHOZAHtenapanor	ARDX	small molecule	NHE3 inhibitor	CMC · Jul 26

Prior ARWR reactions to Readout events

1 historical event · base rate, not prediction

Median 1W move

-16.7%

Median 1M move

-26.2%

Positive outcomes

0/ 1

Negative outcomes

1/ 1

100%

Date	Headline	Outcome	1W	1M	6M
Sep 2024	plozasiran — Phase 3 Topline — Mixed Result	negative	-16.7%	-26.2%	-42.7%

Historical ARWR stock reaction to past Readout catalysts. Past performance is not a forecast — base rates anchor expectations, not outcomes. Positive rate 0%.

Disclosure trail

1 observation · sorted by confidence

Apr 21, 2026·9d agopinned · highest confidence
HIGH confPR
top claim
Q1'27
QTR
“PALISADE, the Phase 3 study of plozasiran in familial chylomicronemia syndrome, is expected to deliver topline data in Q1 2027.”
conf 85%via llm

MethodologyEvery catalyst date is anchored to a primary source. Disclosures with confidence ≥ 0.85 auto-publish; the rest are reviewed by a human within 24 hours. We never interpret data — we organize public information.